Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Firmonertinib misses primary endpoint in Phase 3 FURVENT trial in EGFR exon 20 NSCLC

Written by | 17 Nov 2026 | Internal Medicine

ArriVent BioPharma, Inc. announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review (BICR). Clinical benefit was observed with secondary endpoints such as PFS by investigator’s assessment and confirmed objective response rate by BICR. Although not yet mature, a trend toward an improvement in overall survival was also observed. The safety profile observed in FURVENT was consistent with previous clinical studies of firmonertinib, with no new safety signals identified.

“These disappointing results are not what we hoped for, particularly for the patients with EGFR exon 20 insertion-mutant NSCLC who urgently need more effective treatment options. While the safety profile observed with firmonertinib was consistent with previous clinical studies, FURVENT did not show a meaningful improvement in PFS over chemotherapy by BICR in this study. We are deeply grateful to the patients, investigators and clinical teams who made this program possible and are evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib.” – Bing Yao, Ph.D., Chairman, Chief Executive Officer of ArriVent.

Key Results from the Phase 3 FURVENT Trial

The FURVENT key results are summarized below.

BICR:
Firmonertinib 240mg median PFS: 11.0 months.
Firmonertinib 160mg median PFS: 8.4 months.
Control median PFS: 9.5 months.
p-value (240mg vs. control): 0.0654.
HR (95% CI), 240mg vs Control: 0.75 (0.55, 1.02).
HR (95% CI), 160mg vs Control: 0.91 (0.67, 1.25).
Confirmed ORR 240mg: 60%.
Confirmed ORR 160mg: 35%.
Confirmed ORR control: 33%.

Investigator’s Assessment:
Firmonertinib 240mg median PFS: 11.1 months.
Firmonertinib 160mg median PFS: 8.3 months.
Control median PFS: 7.1 months.
HR (95% CI), 240mg vs Control: 0.61 (0.46, 0.81).
HR (95% CI), 160mg vs Control: 0.86 (0.65, 1.14).
Confirmed ORR 240mg: 61%.
Confirmed ORR 160mg: 41%.
Confirmed ORR control: 28%.

The safety profile observed in FURVENT was consistent with previous clinical studies of firmonertinib, with no new safety signals identified. Treatment-emergent adverse events (TEAE) Grade ≥ 3 were 52% with firmonertinib 240mg, 53% with firmonertinib 160mg, and 55% with the control arm. Treatment-related adverse events (TRAE) Grade ≥ 3 were 26% with firmonertinib 240mg, 22% with firmonertinib 160mg, and 40% with the control arm.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.